Healthcare / BiotechnologyNasdaqGM
$3.44
-0.04 (-1.15%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-25.8M · quality 39.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$346M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-89.1%
↓Gross Margin
86.6%
↑Debt/Equity
1.20
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+56.1%
FCF CAGR
—
FCF margin
-58.9%
FCF / Net income
0.64x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $72.9M · net income $-67.6M · FCF $-42.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $72.9M | $72.9M | $41.5M | $755000.00 | $19.2M |
| Net Income | $-67.6M | $-67.6M | $-36.8M | $-101.1M | $-106.1M |
| EBITDA | $-39.8M | $-39.8M | $-9.5M | $-92.6M | $-76.4M |
| EPS | -0.67 | -0.67 | -0.41 | -1.77 | -2.33 |
| Gross Margin | 86.6% | 86.6% | 77.9% | -882.6% | 55.7% |
| Operating Margin | -45.3% | -45.3% | -143.5% | -12887.8% | -467.7% |
| Net Margin | -92.7% | -92.7% | -88.6% | -13385.3% | -553.6% |
| Balance Sheet | |||||
| Debt/Equity | 1.20 | 1.20 | 0.70 | 1.00 | 0.64 |
| Current Ratio | 1.52 | 1.52 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-42.9M | $-42.9M | $19.1M | $-25.8M | $-89.9M |
| Returns | |||||
| ROE | -89.1% | -89.1% | -28.1% | -119.3% | -90.0% |
| Valuation | |||||
| P/B | 4.54 | 4.54 | 1.16 | 2.02 | 1.09 |
| Growth & Yield | |||||
| Revenue Growth | 75.8% | 75.8% | 5397.5% | -96.1% | — |
| EPS Growth | -63.4% | -63.4% | 76.8% | 24.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+130.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.41 → -0.67
Residual
+130.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.